Quick Takeaways
- Capital Research Global Investors filed SCHEDULE 13G for Vertex Pharmaceuticals Inc. Common Stock (VRTX).
- Disclosed ownership: 5.7%.
- Date of event: 31 Mar 2025.
Capital Research Global Investors - 31 Mar 2025 SCHEDULE 13G Report for Vertex Pharmaceuticals Inc. Common Stock (VRTX)
- Filing Manager
- Capital Research Global Investors
- Reporting Manager
- Capital Research Global Investors
- Symbol
- VRTX
- Shares outstanding
- 255,023,579 shares
- Disclosed Ownership
- 14,536,344 shares
- Ownership
- 5.7%
- Form type
- SCHEDULE 13G
- Filing time
- 13 May 2025, 11:32:29 UTC
- Date of event
- 31 Mar 2025
- Next filing
- 12 Feb 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Capital Research Global Investors disclosed 5.7% ownership in Vertex Pharmaceuticals Inc. Common Stock (VRTX) on 31 Mar 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 13 May 2025, 11:32.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Capital Research Global Investors | 5.7% | 14,536,344 | 14,526,655 | 0 | Jae Won Chung | Vice President and Senior Counsel II, Capital Research and Management Company |